Cytokine-Targeting Antibodies and Immuno-Cytokines

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (10 March 2022) | Viewed by 4767

Special Issue Editor

OSE Immunotherapeutics, Nantes, France
Interests: immunotherapy; immuno-oncology; immuno-inflammation; T and B lymphocytes; macrophages; neutrophils; cytokine

Special Issue Information

Dear Colleagues,

Cytokines are key soluble mediators enabling cell–cell communication between immune cells, but also the crosstalk between our damaged tissue cells and the immune system. Several cytokines or cytokine receptors have been targeted successfully in inflammation and autoimmune diseases with classical antibodies, while the oncology field has focused on administering some naked cytokines. The field of cytokine-targeting antibodies and immuno-cytokines has experienced a growing renewed interest with the discovery and characterization of new cytokines, the introduction of engineered cytokines, multispecific antibodies, and antibody fusion proteins providing novel or redirected mechanisms of action, differentiated functions, and novel therapeutic opportunities.

This Special Issue of Antibodies aims to collect original manuscripts and reviews covering the progress in the growing field of cytokine-targeting antibodies as well as immunocytokines with potential therapeutic application in oncology, inflammation, and autoimmune or infectious diseases.

Dr. Nicolas Poirier
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cytokines
  • antibody engineering
  • bispecific antibodies
  • antibody fusion proteins
  • immuno-cytokines
  • cancer immunotherapy
  • inflammation
  • autoimmune diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 2477 KiB  
Article
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21
Antibodies 2022, 11(1), 19; https://doi.org/10.3390/antib11010019 - 04 Mar 2022
Cited by 4 | Viewed by 4364
Abstract
Interleukin-21 (IL21) is a pleiotropic cytokine involved in the modulation of both innate and adaptive immunity. IL21 is mainly secreted by natural killer (NK) and activated CD4+ T-cells. The biology of this cytokine can be associated to proinflammatory responses reflecting its potent stimulatory [...] Read more.
Interleukin-21 (IL21) is a pleiotropic cytokine involved in the modulation of both innate and adaptive immunity. IL21 is mainly secreted by natural killer (NK) and activated CD4+ T-cells. The biology of this cytokine can be associated to proinflammatory responses reflecting its potent stimulatory activity of NK and CD8+ T-cells. Here we describe four formats of novel IL21-based antibody–cytokine fusion proteins, targeting the extra domain A (EDA) of fibronectin and explore their potential for cancer treatment. The fusion proteins were designed, expressed, and characterized. F8 in single-chain diabody (scDb) format fused to IL21 at its C-terminus exhibited a promising profile in size exclusion chromatography (SEC) and SDS-PAGE. The lead candidate was further characterized in vitro. A cell-based activity assay on murine cytotoxic T-cells showed that human IL21, compared to murine IL21 partially cross-reacted with the murine receptor. The prototype was able to recognize EDA as demonstrated by immunofluorescence analysis on tumor sections. In an in vivo quantitative biodistribution experiment, F8(scDb)-murine IL21 did not preferentially accumulate at the site of disease after intravenous injection, suggesting that additional protein engineering would be required to improve the tumor-homing properties of IL21-based product. Full article
(This article belongs to the Special Issue Cytokine-Targeting Antibodies and Immuno-Cytokines)
Show Figures

Figure 1

Back to TopTop